Allogeneic BMT in a patient with CML and prior disseminated infection by mycobacterium avium complex.

Abstract:

:A patient with chronic myeloid leukemia (CML) who developed a disseminated infection by mycobacterium avium complex (MAC) was successfully treated with rifampin, ethambutol, isoniazid, cycloserin and ciprofloxacin. Diagnosis was proven by histologic examination of hepatic biopsy and culture of the liver biopsy material. Two years later the patient underwent allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor. Antimycobacterial prophylaxis to MAC with ethambutol, cycloserin and ciprofloxacin was given throughout the immediate post-transplant period. On day +25 post-BMT secondary prophylaxis was changed to ciprofloxacin and clarithromycin due to hepatic toxicity. Treatment was maintained until day 100 without side effects. There was no evidence of recurrent mycobacteriosis. Eight months after BMT the patient is well, with a good performance status and chronic graft-versus-host disease (GVHD) limited to the oral mucosa. Thus, MAC infection prior to transplant need not be a contraindication to successful BMT.

journal_name

Bone Marrow Transplant

authors

Hermida G,Richard C,Baro J,Garcia-Ruiz JC,Barreiro G,Fariñas C,Zubizarreta A

subject

Has Abstract

pub_date

1995-07-01 00:00:00

pages

183-5

issue

1

eissn

0268-3369

issn

1476-5365

journal_volume

16

pub_type

杂志文章
  • Acute portal vein thrombosis after autologous stem cell transplantation.

    abstract::Three patients developed abdominal pain and abnormal liver enzymes without hyperbilirubinemia, early after autografting for lymphoma. Two had received conditioning therapy with busulfan, cyclophosphamide and continuous infusion etoposide; the other had received busulfan and melphalan. Doppler ultrasound in all cases d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Grigg A,Gibson R,Bardy P,Szer J

    更新日期:1996-11-01 00:00:00

  • N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

    abstract::Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704143

    authors: Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

    更新日期:2003-08-01 00:00:00

  • Hematopoietic stem cell transplantation in Oman.

    abstract::Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.131

    authors: Dennison D,Al Kindi S,Pathare A,Daar S,Nusrat N,Ur Rehman J,Zia F,Khan H,Khan MI,Alghazaly A,Al Zadjali S,Tauro M,Al Lawatia A,Ganguly S

    更新日期:2008-08-01 00:00:00

  • Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.

    abstract::Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.209

    authors: Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

    更新日期:2008-10-01 00:00:00

  • Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.

    abstract::Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a hi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.169

    authors: Gatz SA,Benninghoff U,Schütz C,Schulz A,Hönig M,Pannicke U,Holzmann KH,Schwarz K,Friedrich W

    更新日期:2011-04-01 00:00:00

  • Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

    abstract::Stroke is an important complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, few studies have been published to analyzed the occurrence and prognosis of stroke after allo-HSCT. From January 2007 to December 2018 in Peking University People's Hospital, 6449 patients receiv...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0903-8

    authors: Cai X,Fu HX,Mo XD,Wang Y,Zhang YY,Wu J,Han W,Tang FF,Gui RY,Chen H,Chen Y,Zhao P,Yan CH,Wang JZ,Chen YH,Chang YJ,Xu LP,Liu KY,Huang XJ,Zhang XH

    更新日期:2020-11-01 00:00:00

  • Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus.

    abstract::Our previous data have revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory systemic lupus erythematosus (SLE) reduced after MSC infusion. This study focused on the roles of mesenchymal SCT (MSCT) in SLE patients with refractory cytopenia. Thirty-five SLE patients with refractory c...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2012.184

    authors: Li X,Wang D,Liang J,Zhang H,Sun L

    更新日期:2013-04-01 00:00:00

  • Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant.

    abstract::Chronic parvovirus B19 infection in the immunocompromised host may cause severe anaemia secondary to failure of erythropoiesis. This has been previously documented in patients with the Acquired Immune Deficiency Syndrome (AIDS), congenital immunodeficiencies and in children with acute lymphoblastic leukaemia during ma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Corbett TJ,Saw H,Popat U,MacMahon E,Cohen BJ,Knowles WA,Beard S,Prentice HG

    更新日期:1995-11-01 00:00:00

  • Successful pregnancy in a 28-year-old patient autografted for acute lymphoblastic leukemia following myeloablative treatment including total body irradiation.

    abstract::We report a successful pregnancy in a woman who at the age of 28 years received total body irradiation (TBI; 7.5 Gy) and high-dose chemotherapy prior to autografting of purged bone marrow for acute lymphoblastic leukemia. Four years after transplantation she delivered a healthy girl. Only five previous cases of succes...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Samuelsson A,Fuchs T,Simonsson B,Björkholm M

    更新日期:1993-12-01 00:00:00

  • Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

    abstract::Four patients with acute myeloid leukaemia relapsed within 6 months of allogeneic BMT. Three patients were treated with cytosine arabinoside and amsacrine while the fourth received no chemotherapy. All patients received infusions of leucocytes obtained by repeated leukapheresis from the original bone marrow donor. Thr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Szer J,Grigg AP,Phillips GL,Sheridan WP

    更新日期:1993-02-01 00:00:00

  • Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.

    abstract::A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705665

    authors: Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

    更新日期:2007-06-01 00:00:00

  • Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation.

    abstract::Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702569

    authors: Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

    更新日期:2000-09-01 00:00:00

  • Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

    abstract::Twenty-nine pediatric allogeneic bone marrow transplant (BMT) recipients, ages 2-17 years, were followed prospectively for cytomegalovirus (CMV) infection. Patients at risk received ganciclovir (GCV) prophylactically at a dose of 5 mg/kg/day i.v., 3 to 5 days per week, until day 100. Surveillance blood and urines were...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Canpolat C,Culbert S,Gardner M,Whimbey E,Tarrand J,Chan KW

    更新日期:1996-04-01 00:00:00

  • Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population.

    abstract::This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T>C), -863 (C>A), -857 (C>T), -238 (G>A), TNFB+252 (A>G) an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.135

    authors: Xiao HW,Lai XY,Luo Y,Shi JM,Tan YM,He JS,Xie WZ,Li L,Zhu XL,Zhu JJ,Sun J,Wei GQ,Jin L,Liu LZ,Wu KN,Yu XH,Cai Z,Lin MF,Ye XJ,Huang H

    更新日期:2011-03-01 00:00:00

  • Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

    abstract::Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2014.238

    authors: Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

    更新日期:2015-02-01 00:00:00

  • Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation.

    abstract::We sought to assess if leaving in place a previously inserted noncolonized or infected implantable catheter (IC) is associated with an increase in morbidity in patients undergoing autologous peripheral stem cell transplantation (APSCT). Medical records from all patients between March 1997 and January 2002 undergoing A...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705018

    authors: Miceli MH,Dong L,Coria P,Vila A,Estrada S,Garcia-Damiano MC,Martinez-Rolón J,Milone G,Dignani MC

    更新日期:2005-07-01 00:00:00

  • Unrelated donor stem cell transplantation in adult patients with thalassemia.

    abstract::Allogeneic SCT remains the only potential cure for patients with thalassemia. However, most BMT candidates lack a suitable family donor and require an unrelated donor (UD). We evaluated whether BMT using UDs in high-risk adult thalassemia patients can offer a probability of cure comparable to that reported employing a...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705173

    authors: La Nasa G,Caocci G,Argiolu F,Giardini C,Locatelli F,Vacca A,Orofino MG,Piras E,Addari MC,Ledda A,Contu L

    更新日期:2005-12-01 00:00:00

  • Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT.

    abstract::We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105)...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01007-w

    authors: Gagelmann N,Eikema DJ,de Wreede LC,Rambaldi A,Iacobelli S,Koster L,Caillot D,Blaise D,Remémyi P,Bulabois CE,Passweg J,Leleu X,Zver S,Kobbe G,Ljungman P,Chevallier P,Ringhoffer M,Martin M,Salmenniemi U,Poiré X,Lenh

    更新日期:2021-01-01 00:00:00

  • Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

    abstract::The International Bone Marrow Transplant Registry (IBMTR), established in 1972, collects data on recipients of allogeneic bone marrow transplants from over 320 institutions, worldwide. Its database includes information for about 40% of all allogeneic transplants performed between 1964 and 1995. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Horowitz MM,Rowlings PA,Passweg JR

    更新日期:1996-05-01 00:00:00

  • Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS).

    abstract::Severe veno-occlusive (VOD) disease is a major cause of morbidity and mortality in allogeneic bone marrow transplant recipients, and new approaches in managing patients who develop serious VOD is needed. In this report, we describe a patient who underwent transjugular intrahepatic portosystemic stent-shunt (TIPS) for ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lévy V,Azoulay D,Rio B,Vincent F,Rabbat A,Hunault M,Bazarbachi A,Delmer A,Zittoun R

    更新日期:1996-08-01 00:00:00

  • The number of circulating CD34+ blood cells predicts the colony-forming capacity of leukapheresis products in children.

    abstract::In children, only a few guidelines are available for optimizing peripheral blood progenitor cell (PBPC) harvesting. We analyzed by means of flow cytometry and clonogenic assays 60 harvest products obtained from 20 children by standardized leukapheresis after treatment with chemotherapy and CSF. In addition, 27 fresh b...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Leibundgut K,von Rohr A,Brülhart K,Hirt A,Ischi E,Jeanneret C,Muff J,Ridolfi-Lüthy A,Wagner HP,Tobler A

    更新日期:1995-01-01 00:00:00

  • Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.

    abstract::A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2014.201

    authors: Mannis GN,Logan AC,Leavitt AD,Yanada M,Hwang J,Olin RL,Damon LE,Andreadis C,Ai WZ,Gaensler KM,Greene CC,Gupta NK,Kaplan LD,Mahindra A,Miyazaki Y,Naoe T,Ohtake S,Sayre PH,Smith CC,Venstrom JM,Wolf JL,Caballero L

    更新日期:2015-01-01 00:00:00

  • Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors.

    abstract::We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematoc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701310

    authors: Martínez AM,Sastre A,Muñoz A,Badell I,Maldonado MS,Cubells J

    更新日期:1998-07-01 00:00:00

  • A risk-adapted approach to acute GVHD treatment: are we there yet?

    abstract::Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.261

    authors: Holtan SG,MacMillan ML

    更新日期:2016-02-01 00:00:00

  • Alternative donor SCT for the treatment of MHC class II deficiency.

    abstract::MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.140

    authors: Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

    更新日期:2013-02-01 00:00:00

  • High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

    abstract::Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2012.14

    authors: Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

    更新日期:2012-10-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation.

    abstract::Thrombotic microangiopathy is one of the complications of bone marrow transplantation and is related to other complications such as graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, and cytomegalovirus infection. Thrombotic microangiopathy occurred in three out of 12 patients who underwen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701890

    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Kanamaru A,Kakishita E

    更新日期:1999-08-01 00:00:00

  • rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells.

    abstract::Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704711

    authors: Lassailly F,Sielleur I,Blaise D,Chabannon C

    更新日期:2005-01-01 00:00:00

  • Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

    abstract::Donor cell-derived leukemia (DCL) is a rare complication of SCT. Here, we present a case of DCL following cord blood transplantation (CBT) and review the clinical features of previously reported DCL. To our knowledge, this is the first report comparing clinical characteristics of DCL from the standpoint of the transpl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2013.127

    authors: Shiozaki H,Yoshinaga K,Kondo T,Imai Y,Shiseki M,Mori N,Teramura M,Motoji T

    更新日期:2014-01-01 00:00:00

  • Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD.

    abstract::Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Pretransplant conditioning regimes cause release of proinflammatory cytokines that stimulate alloreactive donor T cells to attack recipient tissues. IL-10 has been shown to directly downregulate CD4+ T cells...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705218

    authors: Weston LE,Geczy AF,Briscoe H

    更新日期:2006-01-01 00:00:00